Education
About Us
Working with TipRanks
Follow Us
MicroTech Medical (Hangzhou) Co., Ltd. Class H (HK:2235)
:2235
2235 Stock Chart & Stats
HK$7.10
-HK$0.10(-1.77%)
At close: 4:00 PM EST
HK$7.10
-HK$0.10(-1.77%)
Day’s Range― - ―
52-Week RangeHK$4.57 - HK$9.17
Previous CloseN/A
Volume41.60K
Average Volume (3M)340.61K
Market Cap
HK$3.09B
Enterprise ValueHK$1.03B
Total Cash (Recent Filing)HK$1.72B
Total Debt (Recent Filing)HK$30.83M
Price to Earnings (P/E)―
Beta0.31
Next Earnings
Apr 01, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding169,175,840
10 Day Avg. Volume114,320
30 Day Avg. Volume340,611
Financial Highlights & Ratios
PEG Ratio0.79
Price to Book (P/B)1.22
Price to Sales (P/S)6.98
P/FCF Ratio-11.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$13.70Price Target Upside92.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained top-line growth demonstrates expanding adoption of its diabetes devices and recurring consumables. Continued revenue momentum supports scale, enabling investment in R&D, distribution and commercialization that can drive durable improvements in unit economics over the medium term.
Healthy Gross MarginA gross margin above 50% indicates strong unit economics for devices and consumables, providing structural cushion to absorb SG&A and R&D spend. This margin base supports the potential for operating leverage and sustainable profitability if operating costs are managed.
Very Low LeverageMinimal debt reduces interest burden and refinancing risk, giving management flexibility to fund product development, market expansion and working capital from equity or internal cash. A strong equity base enhances resilience through reimbursement cycles or demand variability.
Bears Say
Negative Net Profit MarginAn -18% net margin shows the company remains loss-making after operating and non-operating items, signaling structural profitability gaps. Without meaningful cost reductions, pricing power or higher-volume leverage, losses are likely to persist and constrain retained earnings.
Negative Operating And Free Cash FlowNegative OCF and FCF limit the firm's ability to self-fund growth, invest in commercialization or build cash cushions. Persistent cash burn raises reliance on external financing, increasing dilution risk and potentially constraining strategic initiatives over the next several quarters.
Negative Return On EquityA negative ROE implies the business is not converting invested equity into profitable returns, reflecting operational inefficiencies or elevated costs. Continued negative ROE can erode investor confidence and limit access to lower-cost capital needed for expansion.
MicroTech Medical (Hangzhou) Co., Ltd. Class H News
2235 FAQ
What was MicroTech Medical (Hangzhou) Co., Ltd. Class H’s price range in the past 12 months?
MicroTech Medical (Hangzhou) Co., Ltd. Class H lowest stock price was HK$4.57 and its highest was HK$9.17 in the past 12 months.
What is MicroTech Medical (Hangzhou) Co., Ltd. Class H’s market cap?
MicroTech Medical (Hangzhou) Co., Ltd. Class H’s market cap is HK$3.09B.
When is MicroTech Medical (Hangzhou) Co., Ltd. Class H’s upcoming earnings report date?
MicroTech Medical (Hangzhou) Co., Ltd. Class H’s upcoming earnings report date is Apr 01, 2026 which is in 37 days.
How were MicroTech Medical (Hangzhou) Co., Ltd. Class H’s earnings last quarter?
MicroTech Medical (Hangzhou) Co., Ltd. Class H released its earnings results on Aug 29, 2025. The company reported -HK$0.006 earnings per share for the quarter, beating the consensus estimate of -HK$0.079 by HK$0.074.
Is MicroTech Medical (Hangzhou) Co., Ltd. Class H overvalued?
According to Wall Street analysts MicroTech Medical (Hangzhou) Co., Ltd. Class H’s price is currently Undervalued.
Does MicroTech Medical (Hangzhou) Co., Ltd. Class H pay dividends?
MicroTech Medical (Hangzhou) Co., Ltd. Class H does not currently pay dividends.
What is MicroTech Medical (Hangzhou) Co., Ltd. Class H’s EPS estimate?
MicroTech Medical (Hangzhou) Co., Ltd. Class H’s EPS estimate is 0.09.
How many shares outstanding does MicroTech Medical (Hangzhou) Co., Ltd. Class H have?
MicroTech Medical (Hangzhou) Co., Ltd. Class H has 169,175,840 shares outstanding.
What happened to MicroTech Medical (Hangzhou) Co., Ltd. Class H’s price movement after its last earnings report?
MicroTech Medical (Hangzhou) Co., Ltd. Class H reported an EPS of -HK$0.006 in its last earnings report, beating expectations of -HK$0.079. Following the earnings report the stock price went up 14.113%.
Which hedge fund is a major shareholder of MicroTech Medical (Hangzhou) Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2235
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MicroTech Medical (Hangzhou) Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.72%
12-Months-Change
Fundamentals
Return on Equity
-1.39%
Trailing 12-Months
Asset Growth
3.83%
Trailing 12-Months
Company Description
MicroTech Medical (Hangzhou) Co., Ltd. Class H
MicroTech Medical (Hangzhou) Co., Ltd. engages in the research and development, manufacture, and commercialization of diabetes management medical devices and consumables in the People's Republic of China and internationally. Its products include Equil Patch insulin pump systems, AiDEX continuous glucose monitoring systems, POCT analyzer systems, blood glucose monitoring systems, and closed-loop artificial pancreas. The company is also involved in engineering and technology research experimentation and development activities. MicroTech Medical (Hangzhou) Co., Ltd. was incorporated in 2011 and is headquartered in Hangzhou, the People's Republic of China.
2235 Stock 12 Month Forecast
Average Price Target
HK$13.70
▲(92.96% Upside)
Technical Analysis
Peijia Medical Ltd.
―
Acotec Scientific Holdings Limited
―
MicroPort CardioFlow Medtech Corp.
―
MicroPort NeuroTech Limited
―
Venus Medtech (Hangzhou), Inc. Class H
―
Options Prices
Currently, No data available
---